Loading clinical trials...

Efficacy and Safety of rTMS for Cognitive Rehabilitation in Moyamoya Disease | Clinical Trials | Clareo Health

UNKNOWNNA

Efficacy and Safety of rTMS for Cognitive Rehabilitation in Moyamoya Disease

NCT03543748•Huashan Hospital

Summary

The purpose of this study is to evaluate the safety and effectiveness of transcranial magnetic stimulation (TMS) therapy in moyamoya patients who received surgical revascularization.

Detailed Description

Primary Outcome Measures: TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition \[ Time Frame: Neuropsychological Assessments: Baseline（7days after STA-MCA bypass surgery）; 2 months after TMS treatment Changes in one or more assessed cognitive domains at baseline will be measured by comparing the scores for the different neuropsychological tests. Secondary Outcome Measures: Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation \[ Time Frame: MRI: Baseline and two months after TMS stimulation \] MRI analysis will measure any changes in cortical thickness (mm) or other structural changes in the brain after TMS or Sham-TMS stimulation Change in executive functioning measured as resting-state functional MRI (fMRI) sequence \[ Time Frame: MRI: Baseline and two months after TMS stimulation \] fMRI analysis will measure any changes in amplitude of low frequency fluctuation(ALFF) and other functional changes after TMS stimulation compared to baseline.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. right-handed Chinese population aged 18-80 years;
•2. No evidence of infarct in the cerebral cortex, basal ganglia, brainstem, or cerebellum, but small patches of hyper intense signal neither larger than the arbitrary cut off of 8 mm in maximum dimension on T2-weighted MR images no cystic in the cerebral subcortical white matter could be involved;
•3. No evidence of intracerebral hemorrhage;
•4. diagnosis through digital subtraction angiography;
•5. physically capable of cognitive evaluation;
•6. absence of significant psychiatric disorders or neurological diseases;
•7. No evidence of perioperative epilepsy.

Exclusion Criteria

•1. Significant neurological diseases or psychiatric disorders that could affect cognition
•2. Other cerebrovascular diseases (such as atherosclerosis or vasculitides) likely to cause focal cerebral ischemia
•3. Concomitant cerebrovascular diseases (such as aneurysms or arteriovenous malformation) that need surgical intervention
•4. Severe systemic diseases pregnant or perinatal stage women
•5. Any diseases likely to death within 2 years
•6. Taking drugs such as benzodiazepine clonazepam
•7. Allergy to iodine or radiographic contrast media
•8. Concurrent participation in any other experimental treatment trial

Key Dates

Start Date

August 1, 2018

Primary Completion Date

January 1, 2019

Completion Date

March 1, 2019

Last Updated

June 1, 2018

Enrollment

ESTIMATED participants

Conditions

Moyamoya Disease

Interventions

Transcranial Magnetic Stimulation

DEVICE

Sham Transcranial Magnetic Stimulation

DEVICE

Cognitive-Motor Incorporated Training and Its Relations in Cerebrovascular Diseases With Cognitive and Motor Impairments

NCT07144930

Moyamoya DiseaseHealthy+1 more

View study

RECRUITING

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

NCT05332756

Moyamoya Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 1, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of rTMS for Cognitive Rehabilitation in Moyamoya Disease

Inclusion Criteria

Exclusion Criteria

Cognitive-Motor Incorporated Training and Its Relations in Cerebrovascular Diseases With Cognitive and Motor Impairments

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

Neurosurgical Outcome Network

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease

Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease